iRhythm Technologies, Inc. has voluntarily deregistered its Common Stock.
The company has completed a holding company reorganization.
iRhythm Holdings, Inc. now serves as the new public entity for shareholders.
The changes affect the stock associated with NasdaqGS:IRTC and the prior operating company.
iRhythm focuses on cardiac monitoring solutions, so any change in its corporate structure tends to attract attention from investors who follow medical technology names. The move to a holding...
CVS Health (CVS) closed out FY 2025 with fourth quarter revenue of US$105.1 billion, Basic EPS of US$2.32 and net income of US$2,943 million, following a year in which trailing twelve month revenue reached US$399.8 billion, Basic EPS stood at US$1.40 and net income was US$1,768 million. The company has seen quarterly revenue move from US$96.9 billion in Q4 2024 to US$105.1 billion in Q4 2025, while Basic EPS shifted from US$1.31 to US$2.32 over the same period, against a backdrop of a...
Q1 2026 results and what they signal for Lee Enterprises
Lee Enterprises (LEE) has opened fiscal 2026 with Q1 revenue of US$130.1 million and a basic EPS loss of US$0.92, alongside a trailing 12 month EPS loss of US$4.34 that keeps the story firmly in loss making territory. Over recent quarters, the company has seen revenue move from US$144.6 million in Q1 2025 to US$130.1 million in Q1 2026, while quarterly basic EPS has ranged from a loss of US$2.80 in Q1 2025 to a loss of US$0.92 in the...
Amkor Technology (AMKR) has just posted its FY 2025 numbers, with Q4 revenue of about US$1.9b, basic EPS of US$0.69 and net income excluding extra items of US$171.8m. Trailing twelve month EPS sits at US$1.51 on revenue of roughly US$6.7b and net income of US$373.9m. Over recent quarters the company has seen revenue move from US$1.32b and EPS of US$0.09 in Q1 2025 to US$1.99b and EPS of US$0.51 in Q3 2025, before landing at Q4’s US$1.9b and US$0.69. This sets up a picture where margins are...
Lear Corporation recently reported its full-year 2025 results, with sales of US$23,259.1 million and net income of US$436.8 million, while also providing 2026 guidance for net sales of US$23,210 million to US$24,010 million and core operating earnings of US$1,030 million to US$1,200 million.
The company also disclosed completing a long-running share repurchase program, buying back 35,844,054 shares since 2013 for US$4.41 billions, including 1,632,456 shares for US$175 million in late 2025,...
Unitil (UTL) has wrapped up FY 2025 with fourth quarter revenue of US$161.5 million, basic EPS of US$1.05 and net income of US$19.2 million. On a trailing twelve month basis, revenue sits at US$536 million with basic EPS of US$2.97 and net income of US$50.2 million. The company has seen revenue move from US$494.8 million to US$536 million over recent trailing periods, with basic EPS shifting from US$2.93 to US$2.97, presenting a picture where steady profit generation aligns with largely...
Trimble (TRMB) FY 2025 results set the stage for a margins debate
Trimble (TRMB) closed FY 2025 with fourth quarter revenue of US$969.8 million and basic EPS of US$0.66, putting concrete numbers around its latest report for investors watching both the top and bottom line. The company has seen quarterly revenue move from US$875.8 million in Q3 FY 2024 to US$901.2 million in Q3 FY 2025 and US$969.8 million in Q4 FY 2025, while basic EPS has gone from US$0.17 in Q3 FY 2024 to US$0.47 in Q3 FY...
AECOM Q1 2026 Earnings Snapshot
AECOM (ACM) has opened fiscal 2026 with Q1 revenue of US$3.8b and basic EPS of US$1.07, setting the tone for how its engineering and infrastructure pipeline is flowing through to the bottom line. The company has seen quarterly revenue move from US$4.0b in Q1 2025 to US$3.8b in Q1 2026, while basic EPS has shifted from US$1.34 to US$1.07 over the same period, with trailing twelve month EPS at US$4.56 supported by net income of US$601.3m. For investors, the key...
Neumora Therapeutics, Inc. recently presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11 at the Lotte New York Palace Hotel in New York.
This appearance places Neumora in front of a concentrated audience of biotech-focused investors and analysts, potentially sharpening focus on its pipeline and corporate story.
We’ll now examine how Neumora’s participation in a high-profile Guggenheim biotech summit shapes its investment narrative and investor...
If you are wondering whether Global Business Travel Group’s current share price reflects its true worth, you are not alone. The stock invites a closer look at what you are actually paying for today.
The share price closed at US$5.46, with returns of an 11.2% decline over 7 days, a 33.0% decline over 30 days, a 27.4% decline year to date and a 37.8% decline over 1 year, putting recent performance front and center for anyone thinking about risk and potential reward.
Recent coverage around...
Are you wondering whether Matson at around US$160.66 is offering fair value today, or if the recent run has left the stock looking stretched for new investors like you?
The share price has seen a 21.7% return over the last 30 days, on top of a 29.9% return year to date and 142.2% over 3 years. However, the last 7 days show a 2.8% decline that may have some investors reassessing the balance of risk and opportunity.
Recent attention on Matson has centered on its position in US shipping and...
As February begins, U.S. stock markets have shown strong upward momentum with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting investor optimism despite ongoing economic uncertainties such as government shutdowns and trade negotiations. Amidst this backdrop, small-cap stocks in the S&P 600 may present intriguing opportunities for investors seeking value, especially when insider activity suggests potential confidence in these companies' prospects.
As February 2026 begins, the U.S. stock market is experiencing a strong start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, driven by positive economic indicators such as improved factory activity and new trade deals. In this dynamic environment, high growth tech stocks stand out for their potential to capitalize on technological advancements and evolving market demands, making them an intriguing focus for investors seeking opportunities in a...
As February begins with a strong rally in the U.S. stock markets, highlighted by significant gains in major indices like the Dow Jones Industrial Average and S&P 500, investors are keenly observing growth companies that have shown resilience amidst fluctuating economic conditions. In this context, companies with high insider ownership and robust revenue growth potential stand out as compelling options for those looking to navigate the current market landscape effectively.
As the U.S. stock market kicks off February with a strong performance, highlighted by significant gains in major indices like the Dow Jones and S&P 500, investors are keenly observing opportunities across various sectors. Penny stocks, despite their somewhat outdated moniker, continue to attract interest for their potential to offer value in smaller or newer companies. When these stocks are supported by solid financials, they can present unique growth opportunities for investors seeking...
As February begins, the U.S. stock market has shown a strong start with major indices like the Dow Jones Industrial Average and S&P 500 posting significant gains, reflecting positive investor sentiment amid economic developments such as a new trade deal with India and expanding manufacturing activity. In this dynamic environment, identifying lesser-known stocks that demonstrate resilience and growth potential can be key to diversifying your portfolio effectively.
As February begins, U.S. stock markets have shown a robust performance with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting a positive investor sentiment despite ongoing global economic uncertainties. In such an environment, dividend stocks can be an attractive option for investors seeking steady income and potential growth, as they combine regular payouts with the possibility of capital appreciation amidst fluctuating market conditions.